Core Insights - Lexeo Therapeutics, Inc. is advancing its clinical trial for LX1001, a gene therapy targeting APOE4-associated Alzheimer's disease, with interim data to be presented at the upcoming CTAD conference [1][2] - The Phase 1/2 trial aims to evaluate the safety and efficacy of LX1001 in APOE4 homozygous patients, with enrollment completed in Q4 2023 [2][3] - Approximately 900,000 APOE4 homozygous patients with Alzheimer's disease are estimated to exist in the U.S., highlighting a significant market opportunity for LX1001 [3] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company focused on innovative treatments for genetically defined cardiovascular diseases and Alzheimer's disease [4] - The company employs a stepwise development approach, utilizing early proof-of-concept data to advance its pipeline [4] Clinical Trial Details - The ongoing Phase 1/2 trial is an open-label, dose-ranging study involving 15 patients, assessing safety and multiple efficacy measures, including protein expression and tau and amyloid biomarkers [2][3] - The presentation at the CTAD conference will include 12-month data for patients in Cohorts 1-3 and 6-month data for Cohort 4 [2]
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference